Showing results (131-140 of 2,686) with videos related to

Sort By:
Pageof 269
The Lancet. Infectious Diseases|March 23, 2025
The burden of β-lactam allergy labels in health care: a systematic review and meta-analysisMengyuan Fu, Lin Hu, Kexin Han, et al.
The Lancet. Infectious Diseases|May 4, 2013
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trialC Orla Morrissey, Sharon C-A Chen, Tania C Sorrell, et al.
The Lancet. Infectious Diseases|March 19, 2013
What's in a name? The future of drug-resistant tuberculosis classificationTimothy Sullivan, Yanis Ben Amor
The Lancet. Infectious Diseases|February 23, 2013
HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individualsJohan van Griensven, Ermias Diro, Rogelio Lopez-Velez, et al.
The Lancet. Infectious Diseases|February 26, 2013
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trialMaryline Bonnet, Nilesh Bhatt, Elisabeth Baudin, et al.
The Lancet. Infectious Diseases|July 6, 2013
Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in AsiaYu-Yu Chuang, Yhu-Chering Huang
The Lancet. Infectious Diseases|July 2, 2013
Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled studyJeffrey C Kwong, Priya P Vasa, Michael A Campitelli, et al.
The Lancet. Infectious Diseases|January 26, 2013
The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteriaElizabeth M H Wellington, Alistair B Boxall, Paul Cross, et al.
The Lancet. Infectious Diseases|January 22, 2013
A comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsJohn H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases|December 22, 2012
Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effectsLarry W Chang, David Serwadda, Thomas C Quinn, et al.
Pageof 269